What is it about?

The study investigates the potential of the SMC1A (structural maintenance of chromosome protein 1) subunit of the cohesin-core complex as a therapeutic target for human colorectal cancer. The results suggest that SMC1A silencing, combined with anti-VEGF monoclonal antibody (bevacizumab; Avastin), could be a promising therapeutic strategy for colon cancer.

Featured Image

Read the Original

This page is a summary of: The synergism of SMC1A cohesin gene silencing and bevacizumab against colorectal cancer, Journal of Experimental & Clinical Cancer Research, February 2024, Springer Science + Business Media,
DOI: 10.1186/s13046-024-02976-2.
You can read the full text:

Read

Resources

Contributors

The following have contributed to this page